NeoPharm Sets Conference Call and Webcast for First Quarter 2005 Resul

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    LAKE FOREST, Ill.--(BUSINESS WIRE)--April 22, 2005--NeoPharm, Inc. (Nasdaq: NEOL) today announced the date and time for its regularly-scheduled quarterly conference call to discuss corporate developments and financial highlights for the first quarter ended March 31, 2005.
    During the call, Ronald G. Eidell, President and Chief Executive Officer, and Larry Kenyon, Chief Financial Officer, are expected to discuss:

Friday, May 6, 2005 at 10:00 a.m. ET/9:00 a.m. CT

Domestic: 800-688-0836, passcode 74251794 International: 617-614-4072, passcode 74251794

Audio replays will be available through May 13, 2005.

Domestic: 888-286-8010, passcode 16992940 International: 617-801-6888, passcode 16992940

    The live call and replay will also be available via webcast at www.neophrm.com.

    About NeoPharm

    NeoPharm is a publicly traded biopharmaceutical company dedicated to the research, discovery, and commercialization of new and innovative cancer drugs for therapeutic applications. NeoPharm has built its drug portfolio based on two novel proprietary technology platforms: a tumor-targeting platform and the NeoLipid(TM) drug delivery system. The Company has a portfolio of anticancer compounds in various stages of development. Additional information about NeoPharm, recent news releases, and scientific abstracts related to the Company's drug compounds can be obtained by visiting NeoPharm's Website at www.neophrm.com, or calling Paul Arndt at 847-295-8678 x215.

    Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, including, but not limited to, progress and outcomes of clinical trials of the Company's drug product candidates, including the PRECISE Trial, financial projections, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug and non-drug compounds, including, but not limited to the PRECISE Trial, uncertainty regarding the ability of licensees of our drugs, to obtain necessary foreign drug approvals or to adequately develop foreign markets, uncertainty regarding the availability of third party production capacity, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug and non-drug compounds that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products directly or through independent distributors, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.

--30--AC/cg*

CONTACT: NeoPharm, Inc. Larry Kenyon, 847-295-8678 x 210 lkenyon@neophrm.com or Paul Arndt, 847-295-8678 x 215 parndt@neophrm.com

KEYWORD: ILLINOIS INDUSTRY KEYWORD: BANKING MEDICAL DEVICES PHARMACEUTICAL MEDICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: NeoPharm, Inc.

Copyright Business Wire 2005